drugset / Trial / NCT02350218
Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.
Timeline
- Start
- 2015-03
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alprostadil | Unknown | 360 ug | — |
| Subject | Alprostadil | Unknown | 720 ug | — |
Indications
No indication recorded.